Teniposide
- Generic Name
- Teniposide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H32O13S
- CAS Number
- 29767-20-2
- Unique Ingredient Identifier
- 957E6438QA
- Background
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of ...
- Indication
Teniposide is used for the treatment of refractory acute lymphoblastic leukaemia
- Associated Conditions
- Refractory Lymphoblastic Leukemia, Acute, Childhood
- Associated Therapies
- -
Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06048107
- Locations
- 🇨🇳
Zhao Wang, Beijing, China
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: dexamethasoneDrug: vincristine sulfateBiological: rituximabDrug: clofarabineDrug: cyclophosphamideDrug: etoposideBiological: aldesleukinDrug: pegaspargaseDrug: methotrexateDrug: mercaptopurineDrug: cytarabineDrug: mitoxantroneDrug: teniposideDrug: vinblastineBiological: natural killer cell infusionOther: laboratory biomarker analysisProcedure: allogeneic hematopoietic stem cell transplantationDrug: therapeutic hydrocortisoneDevice: CliniMACS
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01700946
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00853008
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Clínica Teknon, Barcelona, Spain
🇪🇸Hospital de Fuenlabrada, Madrid, Spain
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 550
- Registration Number
- NCT00343369
- Locations
- 🇩🇪
Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Germany
🇩🇪Kreskrankenhaus Kinderabteilung, Heide, Germany
🇩🇪Universitaets - Kinderklinik, Leipzig, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: AsparaginaseDrug: MethotrexateDrug: CytarabineDrug: MercaptopurineDrug: G-CSFDrug: VindesineDrug: EtoposideDrug: PrednisoloneDrug: AdriamycinDrug: ThioguanineDrug: TeniposideProcedure: CNS irradiationProcedure: Mediastinal IrradiationProcedure: Stem cell transplantation (SCT)Drug: IdarubicinDrug: FludarabineDrug: Cladribine
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1883
- Registration Number
- NCT00198991
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Registration Number
- NCT00002531
- Locations
- 🇩🇪
Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany
Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-05-14
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004916
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004231
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.